The presence of 2 species of bacteria was associated with an elevated risk for developing pancreatic cancer.
Women with metastatic, HER2-positive breast cancer with tumors that express high levels of HER2 derived the greatest survival benefit from treatment with trastuzumab emtansine (T-DM1), according to research presented at AACR 2013.
Using autologous T-cell immunotherapy to attack leukemia cells showed early promise in two children diagnosed with relapsing acute lymphoblastic leukemia after bone marrow transplant, according to research presented at AACR 2013.
Melanoma survivors often do not take protective measures to prevent skin cancer recurrence, according to research presented at AACR 2013.
The number of benign findings for suspected lung cancers varies by state, suggesting a national lung cancer screening program would vary geographically, according to research presented at AACR 2013.
The RNA interference (RNAi) drug TKM-080301 can be safely administered to patients with advanced solid tumors or lymphoma, and some patients show therapeutic benefit, according to research presented at AACR 2013.
The novel oral selective AKT pathway inhibitor ARQ 092 exhibits a manageable safety profile among patients with advanced solid tumors, according to research presented at AACR 2013.
In KRAS-Mutant Non-Small Cell Lung Cancer, Biomarkers May Predict Sensitivity to Combined MEK/PI3K InhibitionApril 09, 2013
Newly identified biomarkers may predict sensitivity to combined MEK and PI3K inhibition in patients with KRAS-mutant NSCLC, according to research presented at AACR 2013.
Increased exposure to traffic-related air pollution during pregnancy and early life was associated with a higher incidence of acute lymphoblastic leukemia, retinoblastoma, and germ cell tumors, according to research presented at AACR 2013.
Ibrutinib is well tolerated and highly effective in patients with chronic lymphocytic leukemia, according to research presented at AACR 2013.
Dr. Barbara Burtness' recommended abstracts from the American Association for Cancer Research 2013 Annual Meeting.
Combining dendritic cell-based autologous whole tumor antigen vaccination with adoptive lymphocyte transfer using tumor antigen-specific T cells shows promise in treating women with recurrent ovarian cancer, according to research presented at AACR 2013.
Intermittent dosing might delay or prevent the development of vemurafenib resistance and drug-dependent tumor growth in patients with melanoma, according to research presented at AACR 2013.
African American women have worse survival and less treatable breast cancer, but higher mortality observed cannot be attributed entirely to differential diagnosis by subtype, according to research presented at AACR 2013.
Early Safety, Efficacy Demonstrated for Investigational PI3 Kinase Inhibitor GDC-0032 against Some Breast CancersApril 08, 2013
The investigational oral PI3 kinase inhibitor GDC-0032 exhibits a favorable safety profile and early signs of promising activity against PI3 kinase alpha-mutation hormone receptor-positive breast tumors, according to research presented at the American Association for Cancer Research Annual Meeting 2013.
SCH772984 shows promise against tumor growth driven by BRAF and RAS mutations and might prove useful against tumor resistance to BRAF and MEK inhibitors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer